Metabolic Targets in Nonalcoholic Fatty Liver Disease

por Esler, William P., Bence, Kendra K.
Publicado en Cell Mol Gastroenterol Hepatol (2019)

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Liver‐Targeting Acetyl‐CoA Carboxylase Inhibitor (PF‐05221304): A Three‐Part Randomized Phase 1 Study

por Bergman, Arthur, Carvajal‐Gonzalez, Santos, Tarabar, Sanela, Saxena, Aditi R., Esler, William P., Amin, Neeta B.
Publicado en Clin Pharmacol Drug Dev (2020)

Activity-dependent isolation of the presenilin– γ-secretase complex reveals nicastrin and a γ substrate

por Esler, William P., Kimberly, W. Taylor, Ostaszewski, Beth L., Ye, Wenjuan, Diehl, Thekla S., Selkoe, Dennis J., Wolfe, Michael S.
Publicado 2002

Inhibition of Acetyl-CoA Carboxylase 1 (ACC1) and 2 (ACC2) Reduces Proliferation and De Novo Lipogenesis of EGFRvIII Human Glioblastoma Cells

por Jones, Jessica E. C., Esler, William P., Patel, Rushi, Lanba, Adhiraj, Vera, Nicholas B., Pfefferkorn, Jeffrey A., Vernochet, Cecile
Publicado en PLoS One (2017)

Fibrillar β-Amyloid Induces Microglial Phagocytosis, Expression of Inducible Nitric Oxide Synthase, and Loss of a Select Population of Neurons in the Rat CNS In Vivo

por Weldon, Derik T., Rogers, Scott D., Ghilardi, Joseph R., Finke, Matthew P., Cleary, James P., O’Hare, Eugene, Esler, William P., Maggio, John E., Mantyh, Patrick W.
Publicado en J Neurosci (1998)

Acetyl-CoA Carboxylase Inhibition Improves Multiple Dimensions of NASH Pathogenesis in Model Systems

por Ross, Trenton T., Crowley, Collin, Kelly, Kenneth L., Rinaldi, Anthony, Beebe, David A., Lech, Matthew P., Martinez, Robert V., Carvajal-Gonzalez, Santos, Boucher, Magalie, Hirenallur-Shanthappa, Dinesh, Morin, Jeffrey, Opsahl, Alan C., Vargas, Sarah R., Bence, Kendra K., Pfefferkorn, Jeffrey A., Esler, William P.
Publicado en Cell Mol Gastroenterol Hepatol (2020)

Targeting host metabolism by inhibition of acetyl-Coenzyme A carboxylase reduces flavivirus infection in mouse models

por Jiménez de Oya, Nereida, Esler, William P., Huard, Kim, El-Kattan, Ayman F., Karamanlidis, Georgios, Blázquez, Ana-Belén, Ramos-Ibeas, Priscila, Escribano-Romero, Estela, Louloudes-Lázaro, Andrés, Casas, Josefina, Sobrino, Francisco, Hoehn, Kyle, James, David E., Gutiérrez-Adán, Alfonso, Saiz, Juan-Carlos, Martín-Acebes, Miguel A.
Publicado en Emerg Microbes Infect (2019)

Decreasing the Rate of Metabolic Ketone Reduction in the Discovery of a Clinical Acetyl-CoA Carboxylase Inhibitor for the Treatment of Diabetes

por Griffith, David A., Kung, Daniel W., Esler, William P., Amor, Paul A., Bagley, Scott W., Beysen, Carine, Carvajal-Gonzalez, Santos, Doran, Shawn D., Limberakis, Chris, Mathiowetz, Alan M., McPherson, Kirk, Price, David A., Ravussin, Eric, Sonnenberg, Gabriele E., Southers, James A., Sweet, Laurel J., Turner, Scott M., Vajdos, Felix F.
Publicado en J Med Chem (2014)

Discovery and SAR of Novel 2,3‐Dihydroimidazo[1,2‐c]quinazoline PI3K Inhibitors: Identification of Copanlisib (BAY 80‐6946)

por Scott, William J., Hentemann, Martin F., Rowley, R. Bruce, Bull, Cathy O., Jenkins, Susan, Bullion, Ann M., Johnson, Jeffrey, Redman, Anikó, Robbins, Arthur H., Esler, William, Fracasso, R. Paul, Garrison, Timothy, Hamilton, Mark, Michels, Martin, Wood, Jill E., Wilkie, Dean P., Xiao, Hong, Levy, Joan, Stasik, Enrico, Liu, Ningshu, Schaefer, Martina, Brands, Michael, Lefranc, Julien
Publicado en ChemMedChem (2016)

Pharmacologic inhibition of ketohexokinase prevents fructose-induced metabolic dysfunction

por Gutierrez, Jemy A., Liu, Wei, Perez, Sylvie, Xing, Gang, Sonnenberg, Gabriele, Kou, Kou, Blatnik, Matt, Allen, Richard, Weng, Yan, Vera, Nicholas B., Chidsey, Kristin, Bergman, Arthur, Somayaji, Veena, Crowley, Collin, Clasquin, Michelle F., Nigam, Anu, Fulham, Melissa A., Erion, Derek M., Ross, Trenton T., Esler, William P., Magee, Thomas V., Pfefferkorn, Jeffrey A., Bence, Kendra K., Birnbaum, Morris J., Tesz, Gregory J.
Publicado en Mol Metab (2021)